

1. I prefer to work with liquid formulations rather than lyophilised products. Can you still help?

Yes, absolutely. We often develop liquid formulations that are also suitable for lyophilisation. This gives you the flexibility to switch between liquid and lyophilised presentations later on, without requiring additional development work or investment.

2. Why should I choose Biopharma Group as my CDMO partner?

We are a specialist CDMO with deep expertise in lyophilisation. Rather than offering everything, we focus on doing one thing exceptionally well.

Our size allows for flexibility, direct communication and a genuinely collaborative approach. At the same time, we operate within a trusted network of partners, so you still benefit from a streamlined experience with a limited number of points of contact.

For example, in Antibody Drug Conjugates (ADCs) projects we work with partners for mAb production and conjugation, while we focus on formulation development and aseptic fill and finish.

Many larger CDMOs and pharma companies also come to us for troubleshooting, optimisation and technical support. Working directly with us gives you immediate access to that expertise.

3. Do you support both early development and aseptic fill and finish?

Yes. We support projects from early stage formulation and cycle development through to aseptic fill and finish. This continuity helps ensure a smooth transition between phases and reduces risk during scale up. We have done several projects in R&D, preclinical and clinical phases.

4. Can you optimise or reduce my lyophilisation cycle?

Yes. Cycle development and optimisation is one of our core strengths. We often achieve reductions of up to 40 percent in cycle time, while maintaining product quality and stability.

5. What do you do to meet target requirements?

We begin with a clear project qualification phase to define realistic and measurable targets. From there, we follow a structured, step by step approach with regular checkpoints.

This ensures that progress is aligned with expectations and allows us to adapt quickly if needed, reducing overall project risk.

6. Do you provide troubleshooting for existing lyophilisation processes?

Yes. This is most common with large pharma companies that already have in house lyophilisation expertise and require additional support.

With smaller companies, we tend to focus more on risk prevention from the outset, helping to avoid issues rather than resolving them later.

7. Can you support scale up from R&D to aseptic fill and finish?

Yes. We design processes with scale up in mind from the beginning. Our approach ensures that development work translates efficiently into aseptic fill and finish, minimising delays and unexpected challenges.

8. Do you work with other CDMOs or only directly with sponsors?

Both. We work directly with biotech and pharma companies, but we also collaborate with other CDMOs as lyophilisation specialists.

In many cases, we act as an extension of an existing team, supporting specific aspects such as cycle development, optimisation or troubleshooting.

9. Does Brexit have an impact on my project?

No. We have well established processes in place for customs and international shipping, supported by reliable courier partners.

We currently manage a large number of projects across the EU, demonstrating that logistics are handled smoothly and efficiently.

10. What do people say about working with you?

We have collected a range of testimonials and client feedback, which are available on our website.

We also regularly put prospective clients in contact with past clients, so they can openly discuss their experience of working with us.

11. How flexible are you compared to larger CDMOs?

Our size allows us to be highly flexible and responsive. You are not tied into rigid structures or long decision making chains.

Clients often value the ability to communicate directly with technical experts, move quickly and adapt the project as needed.

12. Can you help if I already have a formulation but need lyophilisation expertise?

Yes. We frequently work with existing formulations, assessing their suitability for lyophilisation and optimising both formulation and cycle where needed.

13. Do you only work on biologics, or can you support other product types?

We work across a range of product types, including biologics, small molecules and more complex products such as ADCs.

14. What capabilities do you offer in aseptic fill and finish?

We can handle highly potent and toxic compounds, including products classified up to OEB6.

In addition, we have a separate line dedicated to medical devices, including products for cosmetics and aesthetic medicine.

15. Can you help reduce project risk?

Yes. A large part of our work, particularly with smaller companies, is focused on risk prevention.

By addressing formulation and process challenges early, we help avoid delays, failures and additional costs later in development.

16. How do you approach collaboration with clients?

We work in a highly collaborative way, acting as an extension of your team. Clear communication by allocating a dedicated project manager, shared objectives and transparency are central to how we operate.